Companies Cryptocurrencies
Ovid Therapeutics Inc
Ovid Therapeutics Inc
Exchange: Nasdaq Global Select
IPO Date: 05/05/2017
CEO: Dr. Jeremy Levin
Biotechnology Healthcare 🔗
  • OVID
    symbol
  • price
  • market cap
  • changes
If you bought

shares of Ovid Therapeutics Inc (OVID) on
You would have made
AMOUNT
today.
Old Price $12 Current Price $12

Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 54 full-time employees. The firm is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.

Address: 1460 Broadway Ste 15044 New York City NEW YORK 10036

Stay updated.